QuantRx Biomedical Corporation

Equities

QTXB

US74765N1090

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 01:37:42 2024-02-26 pm EST			5-day change	1st Jan Change
0.004 ^USD	-.--%		-.--%	-49.37%

2022	QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation	CI

Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020

April 15, 2021 at 05:09 pm EDT

QuantRx Biomedical Corporation announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 60,624 compared to USD 201,739 a year ago. Net loss was USD 252,734 compared to USD 621,920 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about QuantRx Biomedical Corporation

QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation	22-08-24	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
QuantRx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt	22-04-14	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-16	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-15	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-17	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-14	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-19	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-15	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-16	CI
Preprogen LLC acquired the acquisition of certain assets from QuantRx Biomedical Corporation for $1.4 million.	17-12-20	CI
QuantRx Biomedical Corporation cancelled the acquisition of Global Cancer Diagnostics Inc.	16-08-16	CI
QuantRx Biomedical Corporation signed a letter of intent to acquire Global Cancer Diagnostics Inc.	15-09-28	CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt	15-04-14	CI
QuantRx Biomedical Corporation Announces Demise of William Fleming, President, Chief Scientific Officer and Director	15-03-26	CI
QuantRx Biomedical Mulls Strategic Partners For Point Of Care	15-03-19	CI
QuantRx Biomedical Corporation Provides Update on Technological Progress of its Genomic Diagnostics Platforms	15-03-04	CI

Chart QuantRx Biomedical Corporation

Duration

Period

More charts

Company Profile

QuantRx Biomedical Corporation has developed its patented miniform pads and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs (the OTC Business). The Company is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents (the Diagnostics Business). The Company's platforms include inSync, Unique and original equipment manufacturer (OEM) branded over-the-counter and laboratory testing products based on its core intellectual property related to the Company PAD technology. Its OTC Business includes commercialization of its InSync feminine hygienic interlabial pad, the Unique Miniform for hemorrhoid application, and other treated miniforms, as well as maintaining established and continuing licensing relationships related to the OTC Business. It also owns certain diagnostic testing technology that is based on its lateral flow patents.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
QUANTRX BIOMEDICAL CORPORATION	-49.37%	315K
THERMO FISHER SCIENTIFIC	+8.09%	220B
DANAHER CORPORATION	+6.75%	185B
INTUITIVE SURGICAL, INC.	+10.76%	133B
BOSTON SCIENTIFIC CORPORATION	+26.71%	107B
SIEMENS HEALTHINEERS AG	-0.57%	62.91B
EDWARDS LIFESCIENCES CORPORATION	+15.74%	53.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.71B
AGILENT TECHNOLOGIES, INC.	-1.46%	40.29B
GE HEALTHCARE TECHNOLOGIES INC.	+11.19%	39.57B

Other Advanced Medical Equipment & Technology